Raise of $7.5m

ADOR Diagnostics raises $7.5m to advance disruptive molecular diagnostics solution for combatting infectious disease

(Rome, Italy; 23 October 2023) ADOR Diagnostics, a developer of advanced in-vitro molecular diagnostic solutions, is pleased to announce that it has secured an investment of $7.5m from new and existing shareholders. The proceeds will be used to advance the development of its unique NATlabTM system.
ADOR Diagnostics, established through cooperation between Adaltis S.R.L (Italy) & Gamida B.V. (Netherlands), two well-known companies in the IVD arena, is developing unique in-vitro syndromic multiplex molecular diagnostic solutions, with a focus on infectious disease, for small- to mid-sized laboratories, doctor offices and point of care testing. The advanced NATlab molecular diagnostic platform, which utilises a novel isothermal rolling circle amplification (RCA) method incorporated in a unique microfluidic cartridge, is designed to allow rapid, sample-to-answer and highly multiplexed assessments of numerous infectious pathogens to render an accurate aetiological diagnosis.
The proceeds of the fundraising will advance the development of the NATlab solution, which is currently undergoing pre-clinical trials at a hospital. This technology has been issued with 11 patents in the US and 8 internationally with others pending.

Dr. Eran Zahavy, CEO of ADOR Diagnostics, said: “We are extremely pleased to have secured this significant investment, which will allow us to further accelerate the development of our transformative molecular diagnostics solution. This is another step towards enabling rapid, highly accurate, widely available testing in a key diagnostic area. For patients suffering from infectious disease and as we have seen from the pandemic, speed of detection and the ability to know the precise cause of an infection is vital to ensuring the correct treatment can be administered quickly, which leads to better patient outcomes, reduced cost of care and saves lives.” About ADOR Diagnostics

ADOR was founded in 2015 by BATM Advanced Communications Ltd (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, as a strategic partnership between Adaltis, a wholly-owned subsidiary of BATM, and Gamida for Life B.V. (‘Gamida’). ADOR’s goal is to develop, manufacture and market in-vitro diagnostics (IVD) solutions, focusing on molecular diagnostics (‘MDx’). ADOR is developing the NATlab system, which is a POC molecular diagnostics platform that uses the IsoThermal amplification (RCA) process to provide rapid sample-to-answer testing of pathogens. The NATlab instrument tests for multiple pathogens using a single cartridge, designed for a specific infectious disease panel, with a syndromic multiplex MDx approach. ADOR develops different cartridges for different infectious disease panels, such as meningitis, respiratory diseases, STDs and more. The Group, through ADOR and Adaltis, is also partnering with the Stop TB Partnership to develop a solution for the rapid and comprehensive diagnosis of tuberculosis.